Jacob Haaber Christensen

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · Annals of Oncology · 2021 · 262 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

The JAK2 V617F mutation involves B‐ and T‐lymphocyte lineages in a subgroup of patients with Philadelphia‐chromosome negative chronic myeloproliferative disorders

Thomas Stauffer Larsen, Jacob Haaber Christensen, Hans Carl Hasselbalch et al. · British Journal of Haematology · 2007 · 160 citations

Medicine, Genetics, Hematology +17

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Kim Linton, Umberto Vitolo, Wojciech Jurczak et al. · The Lancet Haematology · 2024 · 139 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

The Danish National Lymphoma Registry: Coverage and Data Quality

Bente Arboe, Tarec Christoffer El‐Galaly, Michael Roost Clausen et al. · PLoS ONE · 2016 · 117 citations · Full text

Medicine, Oncology, Cancer Epidemiology +12